Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1990-7-26
|
pubmed:abstractText |
Survival of patients with testicular cancer was analysed with records of 3 patients observed during 3 periods between 1966 and 1985. This study was limited to Non Seminomatous Germ Cell Tumors (NSGCT): 922 cases were collected from 17 centres (Centres de Lutte Contre le Cancer) during 3 periods 1966-1974, 1975-1980, 1981-1985. Results indicated that cryptorchidism was present in 8-13% of cases. The age of the patients varied between a few months and 75 years but a large majority were between the ages of 20-40 years (75%). Clinical staging was homogeneous during the 20 years of study with one third of patients in each stage. Study of biological markers was only performed in the last period: alpha-foeto-protein was increased at initial staging in 64% of cases and bèta Human Chorionic Gonadotrophin (beta HCG) in 54%. Actuarial survival rates were stable in each series after 3 years: at 5 years these rates were 44% (1966-1974), 63% (1975-1980) and 79% (1981-1985). This benefit in survival was present in all stages at different time: for stage I, actuarial survival rates were 72% at 5 years initially and 96% and 98% respectively for the last 2 periods. For stage II, these rates were 64% and 65% for the first 2 periods and became similar to stage I for the last study (92%). In stage III, actuarial survival rates were 4% in 1966-1974, 23% for 1975-1980 and 48% for the last period. These results confirm the significant role of chemotherapy with Cisplatinum in stages 2 or 3. For stage I, new and less aggressive treatment was shown to give the same results as the previous one.
|
pubmed:language |
fre
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0007-4551
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
77
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
331-9
|
pubmed:dateRevised |
2009-11-11
|
pubmed:meshHeading |
pubmed-meshheading:1693863-Adolescent,
pubmed-meshheading:1693863-Adult,
pubmed-meshheading:1693863-Aged,
pubmed-meshheading:1693863-Child,
pubmed-meshheading:1693863-Child, Preschool,
pubmed-meshheading:1693863-Choriocarcinoma,
pubmed-meshheading:1693863-Chorionic Gonadotropin,
pubmed-meshheading:1693863-Dysgerminoma,
pubmed-meshheading:1693863-France,
pubmed-meshheading:1693863-Humans,
pubmed-meshheading:1693863-Infant,
pubmed-meshheading:1693863-Male,
pubmed-meshheading:1693863-Middle Aged,
pubmed-meshheading:1693863-Neoplasm Staging,
pubmed-meshheading:1693863-Prospective Studies,
pubmed-meshheading:1693863-Registries,
pubmed-meshheading:1693863-Retrospective Studies,
pubmed-meshheading:1693863-Spermatozoa,
pubmed-meshheading:1693863-Testicular Neoplasms,
pubmed-meshheading:1693863-alpha-Fetoproteins
|
pubmed:year |
1990
|
pubmed:articleTitle |
[Germ cell testicular tumors. Three therapeutic periods].
|
pubmed:affiliation |
Centre GF-Leclerc, Dijon, France.
|
pubmed:publicationType |
Journal Article,
English Abstract
|